Lestaurtinib: A multi-targeted FLT3 inhibitor

Amir T. Fathi, Mark Levis

Research output: Contribution to journalReview articlepeer-review


Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for these patients. Lestaurtinib, a multi-targeted indolocarbazole derivative that potently inhibits FLT3 autophosphorylation in vitro, has been the most extensively studied agent in clinical trials to date. Multiple late-phase trials are underway to study this agent in adult and pediatric leukemia. This article will summarize the historical development of the pharmacology of lestaurtinib, as well as the ongoing investigation of the agent in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)17-26
Number of pages10
JournalExpert review of hematology
Issue number1
StatePublished - 2009


  • Acute myeloid leukemia
  • FLT3
  • Internal tandem duplication
  • Lestaurtinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Lestaurtinib: A multi-targeted FLT3 inhibitor'. Together they form a unique fingerprint.

Cite this